scispace - formally typeset
Search or ask a question

Showing papers by "Yon-Dschun Ko published in 2011"


Journal ArticleDOI
TL;DR: In this article, the authors investigated breast cancer risk associations of eight susceptibility loci identified in GWAS and two putative susceptibility genes in candidate genes in relation to specific breast tumor subtypes.
Abstract: Breast cancers demonstrate substantial biological, clinical and etiological heterogeneity. We investigated breast cancer risk associations of eight susceptibility loci identified in GWAS and two putative susceptibility loci in candidate genes in relation to specific breast tumor subtypes. Subtypes were defined by five markers (ER, PR, HER2, CK5/6, EGFR) and other pathological and clinical features. Analyses included up to 30 040 invasive breast cancer cases and 53 692 controls from 31 studies within the Breast Cancer Association Consortium. We confirmed previous reports of stronger associations with ER+ than ER- tumors for six of the eight loci identified in GWAS: rs2981582 (10q26) (P-heterogeneity = 6.1 × 10(-18)), rs3803662 (16q12) (P = 3.7 × 10(-5)), rs13281615 (8q24) (P = 0.002), rs13387042 (2q35) (P = 0.006), rs4973768 (3p24) (P = 0.003) and rs6504950 (17q23) (P = 0.002). The two candidate loci, CASP8 (rs1045485, rs17468277) and TGFB1 (rs1982073), were most strongly related with the risk of PR negative tumors (P = 5.1 × 10(-6) and P = 4.1 × 10(-4), respectively), as previously suggested. Four of the eight loci identified in GWAS were associated with triple negative tumors (P ≤ 0.016): rs3803662 (16q12), rs889312 (5q11), rs3817198 (11p15) and rs13387042 (2q35); however, only two of them (16q12 and 2q35) were associated with tumors with the core basal phenotype (P ≤ 0.002). These analyses are consistent with different biological origins of breast cancers, and indicate that tumor stratification might help in the identification and characterization of novel risk factors for breast cancer subtypes. This may eventually result in further improvements in prevention, early detection and treatment.

166 citations


Journal ArticleDOI
TL;DR: The MCMM model integrates the pharmacist with responsibilities in patient education and counseling as well as prevention of drug-related problems and can serve as a tool to trigger changes in cancer medication management.

21 citations


Journal ArticleDOI
TL;DR: The data suggest that the c.538G>A variation in ABCC11 does not contribute to breast carcinogenesis in women of European descent, and no evidence for such an association could be observed in Caucasian women.
Abstract: Genetic polymorphisms of human ABC-transporter genes have been suggested to modulate breast cancer risk in the general population. In particular ABCC11 (MRP8), which is highly expressed in breast cancer tissue and involved in the efflux of conjugated estrogen metabolites such as estrone-3-sulfate and estradiol-17beta-glucuronide, has recently been proposed as a potential risk factor for female breast cancer. The wet earwax-associated G-allele of the c.538G>A polymorphism was associated with an increased risk for breast cancer in Japanese women. In contrast, no evidence for such an association could be observed in Caucasian women. We aimed to confirm/refute the association of the c.538G>A variant in ABCC11 with breast cancer risk and/or histo-pathological tumor characteristics in an independent population-based breast cancer case-control study from Germany comprising 1021 cases and 1015 age-matched controls. No association for allele and genotype frequencies of the 538G>A variant in ABCB11 with breast cancer risk was found. Our data suggest that the c.538G>A variation in ABCC11 does not contribute to breast carcinogenesis in women of European descent.

21 citations


Journal ArticleDOI
TL;DR: The data suggest that among the many known transporters common variations of PXR, SLCO1A2, S LCO1B1, SLSL1B3, and SLSO2B1 do not contribute to breast carcinogenesis.
Abstract: Organic anion transporter polypeptides (OATPs, SLCOs) are involved in the uptake of conjugates steroid hormones such as estrone-3-sulfate. It has been suggested that the expression of OATPs in breast tissues could impact breast carcinogenesis and tumor pathology. The nuclear receptor pregnane X receptor (PXR) is involved in the regulation of SLCO1A2 expression. We investigated 31 variants located in PXR, SLCO1A2, SLCO1B1, SLCO1B3, and SLCO2B1 for an association with breast cancer risk and/or histo-pathological tumor characteristics. Polymorphisms were selected on the basis of a known or potential functional consequence and an allele frequency >2%. Genotyping was performed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry using the GENICA population-based breast cancer case–control collection comprising 1,021 cases and 1,015 age-matched controls. Statistical analysis was performed by SAS, and all tests were two-sided. None of the 31 analyzed transporter and PXR polymorphisms showed an association with breast cancer risk or tumor characteristics. Our data suggest that among the many known transporters common variations of PXR, SLCO1A2, SLCO1B1, SLCO1B3, and SLCO2B1 do not contribute to breast carcinogenesis.

19 citations


Journal ArticleDOI
Kristen N. Stevens1, Montserrat Garcia-Closas, Zachary S. Fredericksen1, Matthew L. Kosel1, Vernon S. Pankratz1, John L. Hopper2, Gillian S. Dite2, Carmel Apicella2, Melissa C. Southey2, Marjanka K. Schmidt3, Annegien Broeks3, L.J. van 't Veer3, R.A.E.M. Tollenaar4, P. A. Fasching, Matthias W. Beckmann, Alexander Hein, Arif B. Ekici5, Nicola F. Johnson, Julian Peto6, I dos Santos Silva6, Lorna Gibson6, Elinor J. Sawyer7, Ian Tomlinson8, Michael J. Kerin9, Stephen J. Chanock10, Jolanta Lissowska11, David J. Hunter12, Robert N. Hoover10, Gilles Thomas10, Roger L. Milne13, Ji Arias Pérez, Anna González-Neira13, Javier Benitez13, Barbara Burwinkel14, Alfons Meindl15, Rita K. Schmutzler16, C. R. Bartrar17, Ute Hamann14, Yon-Dschun Ko, Thomas Brüning18, Jenny Chang-Claude14, Rebecca Hein14, Shan Wang-Gohrke19, Thilo Dörk20, Peter Schürmann20, Michael Bremer20, Peter Hillemanns20, Natalia Bogdanova20, J. V. Zalutsky20, Yuri I. Rogov20, Natalia Antonenkova20, Annika Lindblom21, Sara Margolin21, Arto Mannermaa22, Vesa Kataja22, Veli-Matti Kosma22, Jaana M. Hartikainen22, Georgia Chenevix-Trench23, Xiaoqing Chen23, Paolo Peterlongo, Bernardo Bonanni, Loris Bernard, Siranoush Manoukian, Xianshu Wang1, James R. Cerhan1, Celine M. Vachon1, Janet E. Olson1, Graham G. Giles2, Graham G. Giles24, Laura Baglietto24, Laura Baglietto2, Catriona McLean25, Gianluca Severi24, Gianluca Severi2, Esther M. John26, A. Miron12, Robert Winqvist27, K. Pylkäs28, Arja Jukkola-Vuorinen27, Mervi Grip27, Irene L. Andrulis29, Irene L. Andrulis30, Jo Knight30, Gordon Glendon29, Anna Marie Mulligan30, Angela Cox28, Ian W. Brock28, Graeme Elliott31, Simon S. Cross28, P Pharoah32, Alison M. Dunning32, Karen A. Pooley32, Manjeet K. Humphreys32, Jean Wang32, Daehee Kang33, Keun-Young Yoo33, Dong-Young Noh33, Suleeporn Sangrajrang, V. Gabrieau34, Paul Brennan34, James McKay34, Hoda Anton-Culver35, Argyrios Ziogas35, Fergus J. Couch1, Douglas F. Easton32 
TL;DR: Common germline variation in PIK3CA does not have a strong influence on the risk of breast cancer, and is not associated with a decreased risk in studies of white Europeans combined.
Abstract: BACKGROUND: Somatic mutations in phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) are frequent in breast tumours and have been associated with oestrogen receptor (ER) expression, human epidermal growth factor receptor-2 overexpression, lymph node metastasis and poor survival. The goal of this study was to evaluate the association between inherited variation in this oncogene and risk of breast cancer. METHODS: A single-nucleotide polymorphism from the PIK3CA locus that was associated with breast cancer in a study of Caucasian breast cancer cases and controls from the Mayo Clinic (MCBCS) was genotyped in 5436 cases and 5280 controls from the Cancer Genetic Markers of Susceptibility (CGEMS) study and in 30 949 cases and 29 788 controls from the Breast Cancer Association Consortium (BCAC). RESULTS: Rs1607237 was significantly associated with a decreased risk of breast cancer in MCBCS, CGEMS and all studies of white Europeans combined (odds ratio (OR) = 0.97, 95% confidence interval (CI) 0.95-0.99, P = 4.6 x 10(-3)), but did not reach significance in the BCAC replication study alone (OR = 0.98, 95% CI 0.96-1.01, P = 0.139). CONCLUSION: Common germline variation in PIK3CA does not have a strong influence on the risk of breast cancer British Journal of Cancer (2011) 105, 1934 - 1939. doi: 10.1038/bjc.2011.448 www.bjcancer.com Published online 27 October 2011 (C) 2011 Cancer Research UK

7 citations


Journal ArticleDOI
TL;DR: The findings suggest that genetic variability in the SCRIB polarity gene does not contribute to breast cancer development.
Abstract: The human homolog of the Drosophila Scribble (SCRIB) tumor suppressor gene encodes a protein that regulates apical-basolateral polarity in mammalian epithelia and controls cell proliferation. Due to the role of cell polarity proteins in human cancers, we investigated whether genetic variability in SCRIB impacts breast carcinogenesis and tumor pathology. Five genetic variants were analyzed for an association with breast cancer risk and histopathological tumor parameters using a single nucleotide polymorphism (SNP) tagging approach. Genotyping of five tag SNPs was performed by TaqMan allelic discrimination and RFLP-based PCR using the GENICA population-based breast cancer case-control collection including 1,021 cases and 1,015 age-matched controls. Odds ratios (OR) and 95% confidence intervals (CI) were calculated by ordinal logistic regression. None of the tag SNPs was associated with breast cancer risk or tumor characteristics. Our findings suggest that genetic variability in the SCRIB polarity gene does not contribute to breast cancer development.

4 citations